2022
Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study
Stavrou E, Qiu J, Zafar A, Tramontano AC, Isakoff S, Winer E, Schrag D, Manz C. Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study. JCO Oncology Practice 2022, 18: e1447-e1453. PMID: 35671420, PMCID: PMC9509057, DOI: 10.1200/op.22.00072.Peer-Reviewed Original ResearchConceptsBreast cancer careCancer carePercent of respondentsCancer CenterDana-Farber Cancer InstituteBreast cancer followMedical oncologist's perspectiveAcademic cancer centerPatient-physician communicationUse of telemedicineMost respondentsTM visitsCancer followRoutine followOncologist's perspectiveOncology visitsPatient adherenceOncology cliniciansClinicians' perceptionsFace visitsBreast cliniciansCancer InstituteSecond opinion consultationPatient carePatient recordsPerceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings
Seah DS, Tayob N, Leone JP, Hu J, Yin J, Hughes M, Scott SM, Lederman RI, Frank E, Sohl JJ, Stadler ZK, Erick TK, Peppercorn J, Winer EP, Silverman SG, Come SE, Lin NU. Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings. Breast Cancer Research And Treatment 2022, 192: 201-210. PMID: 35066788, DOI: 10.1007/s10549-021-06494-z.Peer-Reviewed Original ResearchConceptsAdditional biospecimensMedical oncologistsBreast biopsyBreast tissueBiopsy resultsSingle academic medical centerBreast medical oncologistsPain/discomfortPerceptions of patientsMost medical oncologistsAbnormal breastDiagnostic breast biopsyAcademic medical centerPercutaneous breast biopsyNational Cancer InstituteDonation of bloodCancer CenterDiagnostic biopsyPercutaneous biopsyMedical CenterBiopsyCancer InstitutePatientsOncologistsProcedure risk
2020
Genomic profiling of breast cancer brain metastases reveals targetable alterations.
Kabraji S, Spurr L, Hughes M, Li Y, Leone J, Garrido-Castro A, Barroso-Sousa R, Files J, Kirkner G, Johnson B, Winer E, Cherniack A, Lin N. Genomic profiling of breast cancer brain metastases reveals targetable alterations. Journal Of Clinical Oncology 2020, 38: 2525-2525. DOI: 10.1200/jco.2020.38.15_suppl.2525.Peer-Reviewed Original ResearchBreast cancer brain metastasesTumor mutation burdenCancer brain metastasesBrain metastasesTargetable alterationsGenomic alterationsDana-Farber Cancer InstituteTwo-sided Fisher's exact testPIK3CA/PTENActionable genomic alterationsFisher's exact testNumber alterationsTwo-sided MannWhitney U testPrimary tumorMetastatic tumorsMutation burdenERBB2 amplificationCancer InstituteMultiple comparison correctionCancer-related genesExact testCopy number alterationsGenomic profilingU test
2017
Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.
Di Meglio A, Lin NU, Freedman RA, Barry WT, Winer EP, Vaz-Luis I. Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 316-324. PMID: 28275032, DOI: 10.6004/jnccn.2017.0031.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerDe novo metastatic breast cancerNovo metastatic breast cancerTM testingPET/PET-CTTumor markersBreast cancerPET-CTDisease sitesDana-Farber Cancer InstituteSerum tumor markersTiming of imagingPET-CT scanFrequency of imagingCourse of treatmentPatterns of utilizationAsymptomatic patientsNeurologic symptomsRetrospective cohortClinicopathologic factorsTreatment initiationRadiographic studiesCancer InstitutePatientsTumor subtypes
2016
Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study
Barroso-Sousa R, Paes FR, Vaz-Luis I, Batista RB, Costa RB, Losk K, Camuso K, Metzger-Filho O, Hughes ME, Bunnell CA, Golshan M, Winer EP, Lin NU. Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. The Breast 2016, 30: 136-140. PMID: 27721193, DOI: 10.1016/j.breast.2016.09.013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCase-Control StudiesChemotherapy, AdjuvantCyclophosphamideDoxorubicinFemaleGranulocyte Colony-Stimulating FactorHumansMiddle AgedNeutropeniaPaclitaxelPractice Patterns, Physicians'Retrospective StudiesYoung AdultConceptsGranulocyte-colony stimulating factorDose-dense paclitaxelTreatment delayGroup 1High baseline absolute neutrophil countBaseline absolute neutrophil countSingle-institution retrospective studyDana-Farber Cancer InstituteStimulating factorRoutine G-CSFPercent of patientsRetrospective cohort studyAbsolute neutrophil countMajority of patientsAdverse eventsCohort studyNeutrophil countTreatment cessationProspective studyRetrospective studyT therapyBreast cancerGroup 2PatientsCancer Institute
2015
Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer
Seah DS, Scott S, Guo H, Najita J, Lederman R, Frank E, Sohl J, Stadler Z, Silverman S, Peppercorn J, Winer E, Come S, Lin NU. Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. The Oncologist 2015, 20: 992-1000. PMID: 26240134, PMCID: PMC4571800, DOI: 10.1634/theoncologist.2015-0112.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBiopsy-related painResearch biopsiesMBC patientsMedical oncologistsOncologists' attitudesBreast cancerWillingness of patientsNational Cancer InstituteEligible respondersModifiable factorsAdditional biopsiesCancer CenterNCI centersPatients' willingnessCommon reasonBiopsyCancer InstitutePatientsSelf-administered surveyStandalone procedureTumor biologyAvailability of tissueElicit factorsPotential target
2014
Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.
Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. Journal Of The National Comprehensive Cancer Network 2014, 12: 71-80. PMID: 24453294, DOI: 10.6004/jnccn.2014.0008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMiddle AgedNeoplasm MetastasisNeoplasm StagingReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTriple Negative Breast NeoplasmsConceptsMetastatic breast cancerDuration of chemotherapyLines of therapyBreast cancerTumor subtypesDana-Farber Cancer InstituteSixth-line therapyMedian overall survivalBenefit of chemotherapyResult of progressionWarrants further studyChemotherapy linesChemotherapy regimenProlonged therapyMBC diagnosisMedian durationOverall survivalClinicopathologic characteristicsConsecutive patientsMedian ageClinical benefitMedical recordsChemotherapyCancer InstitutePatients
2013
Q&A: Eric Winer on Neoadjuvant Clinical Trials
Winer E. Q&A: Eric Winer on Neoadjuvant Clinical Trials. Cancer Discovery 2013, 3: 832-832. PMID: 23928759, DOI: 10.1158/2159-8290.cd-nd2013-017.Peer-Reviewed Original Research
2009
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF, America F. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet Oncology 2009, 11: 55-65. PMID: 20005174, PMCID: PMC3058239, DOI: 10.1016/s1470-2045(09)70314-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsClinical Trials, Phase III as TopicCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleFluorouracilGene Expression ProfilingGene Expression Regulation, NeoplasticGenetic TestingHumansKaplan-Meier EstimateLymphatic MetastasisMiddle AgedPatient SelectionPostmenopausePredictive Value of TestsProportional Hazards ModelsRandomized Controlled Trials as TopicReceptors, EstrogenRecurrenceRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionRisk AssessmentTamoxifenTime FactorsTreatment OutcomeUnited StatesConceptsLow recurrence scorePositive breast cancerAnthracycline-based chemotherapyDisease-free survivalHigh recurrence scoreRecurrence scorePositive nodesBreast cancerPostmenopausal womenRetrospective analysisNode-positive breast cancerTamoxifen-alone groupTamoxifen-treated patientsPhase 3 trialNational Cancer InstituteEffect of recurrenceOverall survivalSpecific survivalSurvival benefitCox regressionHigh riskTreatment groupsCancer InstituteChemotherapyPredictive valueClinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C, Vahdat LT, Obel J, Vogelzang N, Markman M, Sweetenham JW, Pfister D, Kris MG, Schuchter LM, Sawaya R, Raghavan D, Ganz PA, Kramer B. Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology. Journal Of Clinical Oncology 2009, 27: 6052-6069. PMID: 19901123, DOI: 10.1200/jco.2009.26.6171.Peer-Reviewed Original ResearchMeSH KeywordsBiomedical ResearchEvidence-Based MedicineFemaleFinancing, GovernmentHealth PolicyHumansMaleMass ScreeningMedical OncologyNeoplasmsPractice Guidelines as TopicPredictive Value of TestsQuality of Health CareQuality of LifeResearch Support as TopicSocieties, MedicalTime FactorsTreatment OutcomeUnited StatesConceptsClinical cancer researchClinical OncologyAmerican SocietyCancer treatmentScreening—A ReportPatients 40 yearsThird of patientsCancer researchCourse of diseaseCancer mortality ratesHealth care accessClinical research programNational Cancer InstituteHigh-quality careClinical research projectsSite of originClinical research enterpriseHigh-quality treatmentPatients' qualityPersonalized cancer medicineASCO'S PRESIDENTCare accessCancer InstituteMortality ratePatient care
2008
Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL. Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology. Journal Of Clinical Oncology 2008, 27: 812-826. PMID: 19103723, PMCID: PMC2645086, DOI: 10.1200/jco.2008.21.2134.Peer-Reviewed Original ResearchConceptsCancer preventionClinical OncologyAmerican SocietyCancer treatmentCancer researchScreening—A ReportThird of peopleNational Cancer InstituteSignificant clinical researchField of oncologyNational Cancer ActAnnual American SocietyCancer survivorsCancer patientsCancer incidenceCurable stageASCO'S PRESIDENTNew therapiesCancer InstituteCancer todayOncology reportsPatientsCancerClinical researchCancer development
2006
Chemotherapy-related amenorrhea in women with early breast cancer: The effect of paclitaxel or dose density
Abusief M, Missmer S, Ginsburg E, Weeks J, Winer E, Partridge A. Chemotherapy-related amenorrhea in women with early breast cancer: The effect of paclitaxel or dose density. Journal Of Clinical Oncology 2006, 24: 10506-10506. DOI: 10.1200/jco.2006.24.18_suppl.10506.Peer-Reviewed Original ResearchRisk of amenorrheaEarly breast cancerBreast cancerDDS therapyPremenopausal womenDana-Farber Cancer InstituteMultivariable logistic regression modelChemotherapy-related amenorrheaLikelihood of amenorrheaAddition of paclitaxelDose densityEffect of paclitaxelLogistic regression modelsAdjuvant chemotherapyTamoxifen useWomen's HospitalMultivariable modelMenstrual functioningAmenorrheaAverage ageCancer InstituteMenstrual dataPatientsAlcohol useTherapy